Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Dec 11;398(10317):2147.
doi: 10.1016/S0140-6736(21)02440-5.

High-dose budesonide for early COVID-19

Brian Lipworth  1 , Rory Chan  2 , Rasads Misirovs  2
Affiliations
Comment

High-dose budesonide for early COVID-19

Brian Lipworth et al. Lancet. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

BL reports non-financial support (equipment) from GSK; grants, personal fees (consulting, talks, and advisory board), and other support (attending American Thoracic Society and European Respiratory Society [ERS]) from AstraZeneca; grants, personal fees (consulting, talks, and advisory board), and other support (attending ERS) from Teva; personal fees (consulting) from Sanofi; and personal fees (consulting, talks, and advisory board) from Circassia, in relation to this Correspondence; personal fees (consulting) from Lupin, Glenmark, Vectura, Dr Reddy, and Sandoz; grants, personal fees (consulting, talks, and advisory board), and other support (attending British Thoracic Society) from Boehringer Ingelheim; and grants and personal fees (advisory board and talks) from Mylan, unrelated to this Correspondence; and BL's son is an employee of AstraZeneca. RC and RM declare no competing interests.

Comment on

References

    1. Yu L-M, Bafadhel M, Dorward J, et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021;398:843–855. - PMC - PubMed
    1. Daley-Yates P, Brealey N, Thomas S, et al. Therapeutic index of inhaled corticosteroids in asthma: a dose-response comparison on airway hyperresponsiveness and adrenal axis suppression. Br J Clin Pharmacol. 2021;87:483–493. - PMC - PubMed
    1. Strauss R, Jawhari N, Attaway AH, et al. Intranasal corticosteroids are associated with better outcomes in coronavirus disease 2019 (COVID-19) J Allergy Clin Immunol Pract. 2021;9:3934–3940. - PMC - PubMed
    1. Wilson AM, Sims EJ, McFarlane LC, Lipworth BJ. Effects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic rhinitis. J Allergy Clin Immunol. 1998;102:598–604. - PubMed